Experimental drug aims to curb brain bleeds in rare genetic disease
Disease control
Ongoing
This study tests an experimental drug, NPI-001 (AT-001), in people with hereditary cystatin C amyloid angiopathy (HCCAA), a rare genetic condition that causes repeated brain bleeding and stroke. The trial includes about 15 participants aged 12 and older who carry the specific L68…
Phase: PHASE2 • Sponsor: Arctic Therapeutics • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC